Arcturus Therapeutics, Inc. is an RNA medicines company. Our versatile RNA therapeutics platform enables development of all types of RNA medicines including small interfering RNA (siRNA), messenger RNA (mRNA), replicon RNA, antisense RNA, microRNA and gene editing therapeutics.
Our proprietary unlocked nucleomonomer agent (UNA) Oligomer technology can be used to target any gene in the human genome, as well the genes of other species, such as viruses, for therapeutic purposes.
Our patented Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) nanoparticle delivery system allows safe and efficient in vivo delivery of all RNA medicines.
We use our innovative technologies to develop RNA medicines that treat rare diseases. We also collaborate with industry leaders including Ultragenyx Pharmaceutical, Inc. to develop novel RNA therapeutics.
March 11, 2018
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
March 9, 2018
Arcturus Therapeutics to Present at Bio Europe on March 13th
March 5, 2018
Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach